Tobidasol Plus Injection

Adult dosage

Adult (based on a 70 kg patient): administer 1000–1500 mL intravenously through drip infusion per day. Administration rate: administer 2 mL per kg of body weight over 60 minutes (45 drops per minute). However, the maximum daily dose should not exceed 100 g of D-Sorbitol.

This medication must be used strictly according to the physician's instructions to ensure safety. It should not be used in patients with severe renal dysfunction or high nitrogen levels in the blood. Patients with liver dysfunction or amino acid metabolism issues should not take this medication. Patients with metabolic disorders affecting nitrogen utilization should also avoid this medication. Patients with cachexia due to heart failure and pulmonary edema should not use this medication. This medication should not be administered to patients with oliguria or anuria. Patients with atrioventricular block and those with severe muscular weakness due to myasthenia gravis should also avoid this medication. It is recommended that children and pregnant women do not take this medication. Patients with dehydration, lactic acidosis, or methanol poisoning should not be treated with this medication. Patients who are genetically unable to digest fructose, those in acidosis, patients receiving excessive fluid administration, and renal failure patients may also be at risk when using this medication. Patients who do not receive sufficient oxygen to their cells, as well as those with a history of myocardial infarction or current myocardial infarction, should avoid this medication. Patients with congestive heart failure, those with edema, and patients with high blood potassium levels or potassium accumulation in the body should use this medication with caution. Patients with reduced renal function and those with diabetes insipidus should also exercise caution. This medication contains sodium bisulfite, which may cause allergic reactions or asthma attacks in sensitive individuals, particularly asthmatics. Rarely, hypersensitivity reactions like skin rash may occur, so if any abnormal symptoms appear, administration should be stopped immediately. Occasionally, gastrointestinal symptoms such as nausea or vomiting may occur. Rapid or excessive administration may cause symptoms such as tachycardia, chest discomfort, and high blood pressure. Rapid high doses of this medication can lead to acidosis. Various symptoms such as fever, chills, headache, and difficulty breathing may sometimes appear, so if any abnormal symptoms occur, medical consultation should be sought immediately. Peripheral vasodilation may lead to blood pressure changes. Metabolic acidosis, electrolyte imbalances, blood sugar fluctuations, vitamin deficiencies or excesses, and other metabolic-related side effects may occur. Renal failure patients should monitor blood urea nitrogen (BUN) levels as they may rise. When administering large doses or using this medication with other electrolyte-containing drugs, attention should be paid to maintaining electrolyte balance. In cases of overdose, metabolic alkalosis may occur, so caution is necessary. Patients with renal, pulmonary, or cardiac diseases should avoid fluid overload and use this medication cautiously. Diabetic patients should frequently check their blood glucose levels during administration. Co-administration with the antibiotic tetracycline may reduce the protein-sparing effect of amino acids. If administered with calcium components, magnesium components may precipitate, so caution is advised. The safety of this medication during pregnancy has not been established; it should only be used when the therapeutic benefits outweigh the risks. In children, liver function may be immature, so the dosage should be reduced, and blood ammonia levels should be monitored frequently. Elderly patients may have diminished bodily functions, so administration should be slower, and doses adjusted accordingly. This medication contains electrolytes, and rapid administration may cause chills or vomiting, so it should be administered slowly intravenously. The medication should be prepared at the correct temperature, and prepared in sterile conditions to prevent infections. Check that the solution is clear before administration, and do not use if the solution is discolored or leaked. If crystallized, it should be re-dissolved by temperature. Caution should be exercised in the rate and quantity of xylitol administration as it may lead to kidney or brain issues when given in large amounts or rapidly. Store unopened in its package, and avoid using damaged containers or packages.

Serious side effects

Urticaria, breathing difficulties, respiratory arrest, shock, bronchospasm, significantly reduced urine output due to renal failure, severe edema, hypertension with edema, severe allergic reactions, severe edema or urination abnormalities.

Mild side effects

• Nausea
• vomiting
• rash
• chest discomfort
• palpitations
• tachycardia
• increased blood pressure
• warmth
• vascular pain
• chills

This medication should be stored in a sealed container at a temperature between 1 and 30 degrees Celsius at room temperature. Storing in this manner helps maintain the medication's effectiveness and prevent deterioration.

Appearance

A colorless transparent liquid in a colorless transparent polypropylene aqueous injection container

Package unit

250 milliliters/box